Skip to main content

Table 1 Studies and cases descriptive characteristics

From: Autologous bone graft in the treatment of post-traumatic bone defects: a systematic review and meta-analysis

Authors Year Treatment period Study type LE (n) Age (y) [range] Male/female Bone defect location (femur/tibia/humerus/foream/other bones) FU (mts)
Ring et al. [16] 2000 nr R-CS IV 15 48 [22 - 80] 9/6 -/-/15/-/- 31
Tu et al. [17] 2001 1990–1993 R-CS IV 48 48 [15 - 62] 40/8 10/32/2/4/- 72
Toh et al. [18] 2001 1983–1998 R-CS IV 19 53 [21 - 84] 17/2 -/19/-/-/- 98
Heitmann et al. [19] 2002 nr R-CS IV 12 43 [16 - 79] 7/5 -/-/12/-/- tn
Muramatsu et al. [20] 2003 1985–2000 R-CS IV 13 51 [27 - 80] 6/7 -/-/13/-/- tn
Pelissier et al. [15] 2003 1984–1999 R(C)-CS IV 40 tn tn tn tn
Yajima et al. [21] 2004 1976–2000 R-CS IV 20 37 [17 - 73] 16/4 9/8/-/2/1 64
Lee et al. [22] 2004 1982–2001 R-CS IV 51 41 [15 - 66] 48/3 -/51/-/-/- nr
Adani et al. [23] 2004 1993–2000 R-CS IV 11 38 [16 - 65] 5/6 -/-/-/11/- tn
Ring et al. [24] 2004 1983–2001 R-CS IV 35 40 [21 - 66] 18/17 -/-/-/35/- 43
Yazar et al. [25] 2004 1993–2000 R-CS IV 61 37.5 [10 - 82] 42/19 7/49/-/-/6 58
Safoury [26] 2005 nr R-CS IV 18 34 [22 - 46] 16/2 -/-/-/18/- 36
Jones et al. [27] 2006 2000–2003 RCT II 15 38 [18 - 71] 13/2 -/15/-/-/- tn
El-Sayed et al. [28] 2007 nr R-CS IV 12 25 [12 - 40] 11/1 -/8/2/2/- 24
Ristiniemi et al. [29] 2007 2000–2004 R-CS IV 23 35 [14 - 75] 16/7 -/23/-/-/- nr
Adani et al. [30] 2008 1994–2004 R-CS IV 13 37 [21 - 62] 10/3 -/-/13/-/- nr
El-Gammal et al. [48] 2008 1995–2004 R(C)-CS IV 13 31.5 [nr] 11/2 -/13/-/-/- 38
Ryzewicz et al. [31] 2009 1998–2007 R(C)-CS IV 18 34.2 [18 - 51] 11/7 -/18/-/-/- nr
Allende et al. [32] 2009 1996–2008 R-CS IV 10 32.8 [11 - 56] 9/1 -/-/4/6/- tn
Cavadas et al. [33] 2010 2000–2008 R-CS IV 41 nr [17 - 64] 39/2 -/41/-/-/- nr
McCall et al. [34] 2010 2003–2007 P-CS IV 21 30.6 [nr] 13/8 5/15/-/1/- nr
Sun et al. [35] 2010 2005–2007 R-CS IV 10 31 [16 - 50] 9/1 3/7/-/-/- 26
Apard et al. [36] 2010 nr R-CS IV 12 40.6 [18 - 74] 10/2 -/12/-/-/- 39
Zhen et al. [37] 2010 2000–2007 R-CS IV 28 31.5 [17 - 56] 21/7 -/28/-/-/- 36
Chai et al. [38] 2010 2005–2007 R-CS IV 16 31 [16 - 50] 10/6 -/9/-/4/3 18
Georgescu et al. [39] 2011 1997–2007 R-CS IV 44 30.5 [5 - 66] 33/11 3/22/5/3/11 23
Chung et al. [40] 2011 1989–2007 R-CS IV 10 25.3 [16 - 43] 8/2 -/10/-/-/- 41
Niu et al. [41] 2011 2003–2008 R-CS IV 19 38.9 [18 - 61] 12/7 8/11/-/-/- nr
Liang et al. [42] 2012 1996–2006 R-CS IV 16 33.3 [21 - 46] nr 16/-/-/-/- 83
Gulan et al. [43] 2012 1991–1998 R-CS IV 10 30 [22 - 51] 10/0 -/10/-/-/- 144
Liang et al. [44] 2012 2001–2007 R-CS IV 14 34.3 [23 - 48] 11/3 14/-/-/-/- 67
Gao et al. [45] 2012 2004–2006 R-CS IV 18 34 [16 - 56] 13/5 7/11/-/-/- 40
Niu et al. [46] 2012 1993–2008 R-CS IV 22 33.8 [17 – 60] 14/8 -/-/22/-/- 39
Özaksar et al. [47] 2012 1993–2009 R-CS IV 21 32 [16 - 47] 19/2 -/21/-/-/- 74
  1. LE level of evidence, n number of patients included in this review, y years, mts months, FU follow-up, R retrospective, P prospective, CS case series, C controlled, RCT randomized controlled trial, nr not reported, tn technical note (see Additional file 3)